Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Brian Kelley
Advertisement
Brian Kelley is vice president, bioprocess development at Genentech, Inc.
Articles by Brian Kelley
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
2
Regulatory Challenges for Global Manufacturing of Vaccines
3
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
4
Welcome to CPHI Frankfurt 2025
5
